News

Shire plans a Phase 4 clinical trial of its parathyroid hormone therapy Natpara as an add-on to standard hypothyroidism treatment. Hypoparathyroidism is caused by abnormal low levels of parathyroid hormone (PTH), which regulates levels of calcium in blood and bones. Low levels of the hormone lead to a  mineral imbalance that…

Treatment of patients with pseudohypoparathyroidism type 1B should involve lowering parathyroid hormone levels to avoid adverse effects on bone, according to a recent study. Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterized by normal renal function and resistance to the action of the parathyroid hormone — a hormone…

Hypoparathyroidism may lead to the development of a rare neurological disorder manifesting with seizures, a case study reveals. The study, “A Case of Seizure Revealing Fahr’s Syndrome with Primary Hypoparathyroidism,” was published in the American Journal of Case Reports. The patient, a 52-year-old man, was admitted…